文献速递骨软组织肉瘤与黑色素瘤

EORTC 2139/COLUMBUS-AD 试验主要分析:高危 II 期 BRAF V600E/K 黑色素瘤辅助 encorafenib 联合 binimetinib 对比安慰剂

primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
PubMed 文献 · Eur J Cancer · 2026-07-21

该随机试验评估切除后高危 IIB/IIC 期 BRAF V600E/K 突变皮肤黑色素瘤患者接受 encorafenib 联合 binimetinib 辅助治疗对比安慰剂的疗效与安全性。因入组提前终止,研究改为以安全性为主要终点、无复发生存为次要终点,共随机 110 例。联合治疗组 12 个月无复发生存率为 86%,安慰剂组为 70%,安全性总体可控。

要点

  • 切除后 IIB/IIC 期 BRAF V600E/K 黑色素瘤可考虑辅助 encorafenib 联合 binimetinib。
  • 联合治疗组 12 个月无复发生存率 86%,安慰剂组 70%。
  • 联合治疗组 ≥3 级治疗相关不良事件发生率 24%,33% 因不良事件永久停药。

核心结论

  • encorafenib 联合 binimetinib 在切除后 IIB/IIC 期 BRAF V600E/K 突变皮肤黑色素瘤中显示出可控的安全性和令人鼓舞的疗效。

研究设计与样本

  • 随机、1:1 对照试验,纳入切除后 IIB/IIC 期 BRAF V600E/K 突变皮肤黑色素瘤成人患者,计划随机 815 例,实际随机 110 例。
  • 因入组提前终止,研究修正为以安全性为主要终点、无复发生存为次要终点。
  • 联合治疗组给予 encorafenib 450 mg 每日一次 + binimetinib 45 mg 每日两次口服,为期一年;对照组为安慰剂。

主要发现

  • 随机患者中 87 例(79%)为 BRAF V600E 突变,39 例(35%)为 AJCC8 IIC 期。
  • 联合治疗组中位随访 12 个月,安慰剂组 7 个月。
  • 54 例启动联合治疗的患者中,13 例(24%)发生 ≥3 级治疗相关不良事件,18 例(33%)因不良事件永久停药。
  • 12 个月无复发生存率:联合治疗组 86%(95%CI 65-95%),安慰剂组 70%(95%CI 46-85%)。
  • 12 个月无远处转移生存率:联合治疗组 92%(95%CI 77-97%),安慰剂组 82%(95%CI 55-93%)。

临床怎么用

  • 对于切除后高危 IIB/IIC 期 BRAF V600E/K 突变皮肤黑色素瘤,可考虑辅助 encorafenib 联合 binimetinib 治疗。
  • 治疗期间需密切监测不良事件,因 ≥3 级治疗相关不良事件和永久停药比例较高。

局限性

  • 研究因入组提前终止,实际样本量仅 110 例,低于计划的 815 例。
  • 随访时间较短,联合治疗组中位随访 12 个月,安慰剂组 7 个月。
  • 主要终点由无复发生存改为安全性,疗效为次要终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stage IIB/IIC melanoma has a high risk of recurrence after resection. Combined BRAF/MEK inhibitor therapy showed benefit in resected high-risk stage III and advanced melanoma. The objective of this study was to investigate its role in stage IIB/IIC. METHODS: Adult patients with resected stage IIB/IIC cutaneous melanoma which had a BRAF V600E/K mutation were randomized 1:1 to receive encorafenib (enco) 450 mg QD + binimetinib (bini) 45 mg BID orally for one year or placebo. The study planned to randomize 815 patients and was designed to demonstrate superiority regarding recurrence-free survival (RFS). Following a premature termination of accrual, the study was amended with safety as the primary endpoint and RFS as secondary endpoint. RESULTS: Between June 9, 2022, and October 9, 2023, 339 patients were screened for a BRAF mutation and 110 randomized. Data cutoff was 19 Nov. 2024, after the last patient discontinued study participation. Among randomized patients, 87 (79%) had a BRAF V600E mutation, and 39 (35%) AJCC8 stage IIC. Median follow-up was 12 and 7 months for enco/bini and placebo arms, respectively. Among 54 patients who initiated enco + bini, grade ≥ 3 treatment-related adverse events (AE) occurred in 13 (24%) patients, and 18 (33%) patients had an AE leading to permanent treatment discontinuation. RFS at 12 months was 86% (95% CI: 65-95%) in the enco + bini and 70% (95% CI: 46-85%) in the placebo arm, distant metastasis-free survival at 12 months was 92% (95% CI: 77-97%) for enco + bini and 82% (95% CI: 55-93%) for placebo. CONCLUSION: EORTC 2139 - Columbus-AD demonstrated a consistent and manageable safety profile and encouraging efficacy results for the combination of enco and bini in resected stage IIB/C BRAF V600E/K-mutated cutaneous melanomas.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. van Akkooi AC, Kicinski M, Govaerts AS, et al. primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma. Eur J Cancer. 2026. PMID: 42501621. doi:10.1016/j.ejca.2026.116951

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。